Non Alcoholic Fatty Liver Disease (NAFLD) – Pipeline Review, H1 2019 – ResearchAndMarkets.com
July 18, 2019DUBLIN–(BUSINESS WIRE)–The “Non Alcoholic Fatty Liver Disease (NAFLD) – Pipeline Review, H1 2019” drug pipelines has been added to ResearchAndMarkets.com’s offering.
Non Alcoholic Fatty Liver Disease (NAFLD) – Pipeline Review, H1 2019, provides comprehensive information on the therapeutics under development for Non Alcoholic Fatty Liver Disease (NAFLD) (Gastrointestinal), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Non Alcoholic Fatty Liver Disease (NAFLD) (Gastrointestinal) pipeline guide also reviews of key players involved in therapeutic development for Non Alcoholic Fatty Liver Disease (NAFLD) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 4, 21, 13, 1, 31 and 9 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 5 molecules, respectively.
Non Alcoholic Fatty Liver Disease (NAFLD) (Gastrointestinal) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Reasons to buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Non Alcoholic Fatty Liver Disease (NAFLD) (Gastrointestinal).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Non Alcoholic Fatty Liver Disease (NAFLD) (Gastrointestinal) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Key Topics Covered:
- Introduction
- Non Alcoholic Fatty Liver Disease (NAFLD) – Overview
- Non Alcoholic Fatty Liver Disease (NAFLD) – Therapeutics Development
- Non Alcoholic Fatty Liver Disease (NAFLD) – Therapeutics Assessment
- Non Alcoholic Fatty Liver Disease (NAFLD) – Companies Involved in Therapeutics Development
- Non Alcoholic Fatty Liver Disease (NAFLD) – Drug Profiles
- Non Alcoholic Fatty Liver Disease (NAFLD) – Dormant Projects
- Non Alcoholic Fatty Liver Disease (NAFLD) – Discontinued Products
- Non Alcoholic Fatty Liver Disease (NAFLD) – Product Development Milestones
- Appendix
Companies Mentioned
- Akcea Therapeutics Inc
- Ardelyx Inc
- AstraZeneca Plc
- Betagenon AB
- BioElectron Technology Corp
- Bird Rock Bio Inc
- Boehringer Ingelheim GmbH
- Cadila Healthcare Ltd
- Can-Fite BioPharma Ltd
- Carmot Therapeutics Inc
- Cerenis Therapeutics Holding SA
- Corcept Therapeutics Inc
- Dr. Falk Pharma GmbH
- DURECT Corp
- Eli Lilly and Co
- Enanta Pharmaceuticals Inc
- Eternygen GmbH
- Evgen Pharma Plc
- F. Hoffmann-La Roche Ltd
- Galmed Pharmaceuticals Ltd
- Gemphire Therapeutics Inc
- GemVax & KAEL Co Ltd
- Gilead Sciences Inc
- Guangdong Zhongsheng Pharmaceutical Co Ltd
- Hanmi Pharmaceuticals Co Ltd
- HemoShear Therapeutics, LLC
- Huons Global Co Ltd
- Immuron Ltd
- Inventiva
- Ionis Pharmaceuticals Inc
- Kinomedica Pty Ltd
- Kowa Co Ltd
- Kyorin Pharmaceutical Co Ltd
- MallInckrodt Plc
- Metacrine Inc
- Mina Therapeutics Ltd
- Novartis AG
- NuSirt Biopharma Inc
- Pfizer Inc
- Phenex Pharmaceuticals AG
- Renova Therapeutics Inc
- Ritter Pharmaceuticals Inc
- Sancilio & Company Inc
- Shenzhen HighTide Biopharmaceutical Ltd
- T3D Therapeutics Inc
- TaiwanJ Pharmaceuticals Co Ltd
- TCM Biotech International Corp
- Theratechnologies Inc
- Tiziana Life Sciences Plc
-
Viking Therapeutics Inc
For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/m7zzzx
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world’s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Contacts
ResearchAndMarkets.com
Laura Wood, Senior Press Manager
[email protected]
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Liver and Kidney Disorders Drugs
